AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.2660
0.00 (0.00%)
At close: Jul 14, 2026, 4:00 PM EDT
0.2665
+0.0005 (0.19%)
After-hours: Jul 14, 2026, 8:00 PM EDT
AIM ImmunoTech Employees
As of December 31, 2025, AIM ImmunoTech had 21 total employees, including 19 full-time and 2 part-time employees. The number of employees decreased by 2 or -8.70% compared to the previous year.
Employees
21
Change (1Y)
-2
Growth (1Y)
-8.70%
Revenue / Employee
$4,476
Profits / Employee
-$632,190
Market Cap
5.87M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -2 | -8.70% | 19 | 2 |
| Dec 31, 2024 | 23 | -5 | -17.86% | 21 | 2 |
| Dec 31, 2023 | 28 | 4 | 16.67% | 26 | 2 |
| Dec 31, 2022 | 24 | 1 | 4.35% | 22 | 2 |
| Dec 31, 2021 | 23 | 0 | - | 21 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| Purple Biotech | 10 |
| XTL Biopharmaceuticals | 10 |
| Adial Pharmaceuticals | 5 |
| Acurx Pharmaceuticals | 4 |
| Silo Pharma | 3 |
| Addex Therapeutics | 3 |
| Xenetic Biosciences | 2 |
AIM News
- 7 days ago - AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program - GlobeNewsWire
- 19 days ago - AIM ImmunoTech Proxy statement: Proxy filing - Filings
- 20 days ago - AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones - GlobeNewsWire
- 21 days ago - AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences - Business Wire
- 22 days ago - AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series - GlobeNewsWire
- 26 days ago - AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer - GlobeNewsWire
- 26 days ago - AIM ImmunoTech Registration statement: Registration filing - Filings
- 27 days ago - AIM Talks China 2026 Convenes in Guangzhou, Advancing Strategic Partnerships and Cross Border Investment Across the Greater Bay Area - GlobeNewsWire